Scholarlink

Background <p>B-cell depletion with the chimeric type I anti-CD20 antibody rituximab has been used off-label in systemic lupus erythematosus (SLE) and lupus nephritis (LN) for over two decades, yet pivotal randomised controlled trials (the EXPLORER and LUNAR studies) failed to achieve their primary endpoints. Obinutuzumab, a glycoengineered type II anti-CD20 humanised monoclonal antibody, induces deeper and more durable B-cell depletion through enhanced antibody-dependent cellular cytotoxicity and reduced antigenic modulation. No systematic comparative review has synthesised the clinical efficacy data—specifically SLE Responder Index-4 (SRI-4) and complete renal response (CRR) rates—across both type I and type II anti-CD20 strategies in SLE/LN.</p> Methods <p>We conducted a narrative comparative review of published randomised controlled trials, prospective cohort studies, and mechanistic studies evaluating rituximab and obinutuzumab in SLE and LN. PubMed was searched from inception through March 2026. Primary outcomes of interest were SRI-4 response rates and CRR rates. Secondary outcomes included serological changes, B-cell depletion kinetics, safety profiles, and treatment durability.</p> Results <p>Eight trials met inclusion criteria. Rituximab failed to demonstrate superiority over placebo in both the EXPLORER (extra-renal SLE) and LUNAR (LN) trials, despite promising real-world data. In contrast, obinutuzumab demonstrated statistically significant improvements in CRR at week 104 in a Phase 2 LN trial (41% vs. 23%; <i>p</i> = 0.026) and, in the Phase 3 ALLEGORY trial (published March 2026), achieved SRI-4 response rates of 76.7% versus 53.5% in placebo-treated patients with active non-renal SLE (adjusted difference, 23.1% points; <i>p</i> &lt; 0.001). Mechanistically, the superior performance of obinutuzumab is attributed to enhanced Fc-gamma receptor engagement, resistance to antigenic modulation, and more profound depletion of memory B-cell subsets known to drive lupus pathogenesis.</p> Conclusions <p>Type II anti-CD20 blockade with obinutuzumab represents a paradigm shift from the perceived failure of B-cell depletion in SLE/LN. The consistent superiority of obinutuzumab across both renal and extra-renal manifestations supports its emergence as a new standard for B-cell-targeted therapy. Future head-to-head trials and biomarker-stratified analyses are warranted to establish the optimal sequencing and patient-selection strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Obinutuzumab versus rituximab in systemic lupus erythematosus and lupus nephritis: a systematic comparative review of type I and type II anti-CD20 strategies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月11日

查看全文
  • Shihshuan Fang,
  • Shenghan Chen

摘要

Background

B-cell depletion with the chimeric type I anti-CD20 antibody rituximab has been used off-label in systemic lupus erythematosus (SLE) and lupus nephritis (LN) for over two decades, yet pivotal randomised controlled trials (the EXPLORER and LUNAR studies) failed to achieve their primary endpoints. Obinutuzumab, a glycoengineered type II anti-CD20 humanised monoclonal antibody, induces deeper and more durable B-cell depletion through enhanced antibody-dependent cellular cytotoxicity and reduced antigenic modulation. No systematic comparative review has synthesised the clinical efficacy data—specifically SLE Responder Index-4 (SRI-4) and complete renal response (CRR) rates—across both type I and type II anti-CD20 strategies in SLE/LN.

Methods

We conducted a narrative comparative review of published randomised controlled trials, prospective cohort studies, and mechanistic studies evaluating rituximab and obinutuzumab in SLE and LN. PubMed was searched from inception through March 2026. Primary outcomes of interest were SRI-4 response rates and CRR rates. Secondary outcomes included serological changes, B-cell depletion kinetics, safety profiles, and treatment durability.

Results

Eight trials met inclusion criteria. Rituximab failed to demonstrate superiority over placebo in both the EXPLORER (extra-renal SLE) and LUNAR (LN) trials, despite promising real-world data. In contrast, obinutuzumab demonstrated statistically significant improvements in CRR at week 104 in a Phase 2 LN trial (41% vs. 23%; p = 0.026) and, in the Phase 3 ALLEGORY trial (published March 2026), achieved SRI-4 response rates of 76.7% versus 53.5% in placebo-treated patients with active non-renal SLE (adjusted difference, 23.1% points; p < 0.001). Mechanistically, the superior performance of obinutuzumab is attributed to enhanced Fc-gamma receptor engagement, resistance to antigenic modulation, and more profound depletion of memory B-cell subsets known to drive lupus pathogenesis.

Conclusions

Type II anti-CD20 blockade with obinutuzumab represents a paradigm shift from the perceived failure of B-cell depletion in SLE/LN. The consistent superiority of obinutuzumab across both renal and extra-renal manifestations supports its emergence as a new standard for B-cell-targeted therapy. Future head-to-head trials and biomarker-stratified analyses are warranted to establish the optimal sequencing and patient-selection strategies.